The final score, which may confirm AD pathology, is obtained by adding the results from CSF biomarkers, including Aβ 1-42 biomarkers (0 = normal; 1 = borderline pathological; 2 = pathological) and Tau/pTau biomarkers (0 = normal; 1 = borderline pathological; 2 = pathological) based on the cut-off values accepted in the laboratory [63,64]. The gene discussed is MAPT; the disease is Alzheimer disease.